 |
|
Established and Emerging Uses of Cytoprotection in Head and Neck Cancer
Arch Otolaryngol Head Neck Surg. 2006;132:129-130.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The delicate balance between the desired and undesired effects of medical treatment is particularly evident in oncology, in which the therapeutic window may be narrow. Radiation and medical oncologists routinely administer therapies that may be toxic to adjacent or distant healthy functional tissues as well as the cancer. Patients and oncologists must accept a certain level of normal tissue toxic effects in exchange for, or along with, therapeutic benefits. The toxic effects associated with chemotherapy and radiotherapy are thus often viewed as a "necessary evil." Unnecessary toxic effects to healthy tissues, however, is not an acceptable consequence of cancer therapy when effective methods for their elimination or amelioration are available, and those methods should not be withheld from patients.
We have made significant strides in symptom management during cancer therapy. For example, medical oncologists have made major gains in the reduction of toxic effects with antiemetics,1 hematologic growth factors,2 and . . . [Full Text of this Article]
AUTHOR INFORMATION
David I. Rosenthal, MD
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Feasibility and Efficacy of Subcutaneous Amifostine Therapy in Patients With Head and Neck Cancer Treated With Curative Accelerated Concomitant-Boost Radiation Therapy
Mahmut Ozsahin, Michael Betz, Oscar Matzinger, Luc Bron, François Luthi, Philippe Pasche, David Azria, René O. Mirimanoff, and Abderrahim Zouhair
Arch Otolaryngol Head Neck Surg. 2006;132(2):141-145.
ABSTRACT
| FULL TEXT
|
